Publications - 'P'
Publications 601 - 625 de 2458
| Titre | DOI |
|---|---|
|
Phakomatosis pigmentovascularis is caused by somatic missense mutations in GNA11: a new addition to the mosaic G protein disorder group A. Thomas; Z. Zeng; R. O'Shaughnessy; J.B. Riviere; R. Waelchli; L. Al-Olabi; S. Loughlin; M. Glover; I. Khan; M. Lapidot; E. Sprecher; M. Wobser; H. Hamm; P. Vabres; E. Patton 2015 |
|
|
Phakomatosis pigmentovascularis spilorosea and speckled lentiginous naevus syndrome are caused by mosaic mutations in the gene PTPN11 S. Polubothu; N. Bender; S. Muthiah; Z. Zeng; M. Boehm; S. Barbarot; V. Carmignac; C. Fink; H.A. Haenssle; R. Happle; S. Malhotra; M. Topf; P. Vabres; E. Patton; N. Rajan; B.A. Drolet; V. AKinsler 2019 |
|
|
Phakomatosis pigmentovascularis spilorosea and speckled lentiginous naevus syndrome are caused by mosaic mutations in the gene PTPN11 S. Polubothu; N. Bender; S. Muthiah; Z. Zeng; M. Boehm; S. Barbarot; V. Carmignac; C. Fink; H.A. Haenssle; R. Happle; S. Malhotra; M. Topf; P. Vabres; E. Patton; N. Rajan; B.A. Drolet; V. AKinsler 2019 |
|
|
Phantom Odors G. Brand 2019 |
|
|
Phantoms in Artists: The Lost Limbs of Blaise Cendrars, Arthur Rimbaud, and Paul Wittgenstein L. Tatu; J. Bogousslavsky; F. Boller 2014 |
10.1080/0964704X.2014.881168 |
|
PHARE randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer X. Pivot; G. Romieu; M. Debled; J.Y. Pierga; P. Kerbrat; T. Bachelot; M. Espie; A. Lortholary; P. Fumoleau; D. Serin; J.P. Jacquin; C. Jouannaud; M. Rios; S. Abadie-Lacourtoisie; L. Venat-Bouvet; L. Cany; S. Catala; D. Khayat; L. Gambotti; I. Pauporte; F. Mercier; S. Paget-Bailly; J. Henriques; J.M. Grouin 2019 |
10.1158/1538-7445.SABCS18-GS2-07 |
|
Pharmaceutical immunoglobulin G impairs anti-carcinoma activity of oxaliplatin in colon cancer cells Y. Shang; X. Zhang; L. Lu; K. Jiang; M. Krohn; S. Matschos; C.Susanne Mullins; B. Vollmar; D. Zechner; P. Gong; M. Linnebacher 2021 |
10.1038/s41416-021-01272-6 |
|
Pharmaceutical science studies, successive reforms E. Adenot; L. Agay; J.P. Belon; A. Piraux 2019 |
10.1016/j.actpha.2018.12.005 |
|
Pharmaceutical spray freeze drying S. Wanning; R. Sueverkruep; A. Lamprecht 2015 |
10.1016/j.ijpharm.2015.04.053 |
|
Pharmacists' point of view on the conference chemotherapy foundation symposium report organized in New York (6-8 November 2013) O. Aujoulat; F. Basuyau; N. Cormier; D. Dautel; F. De Crozals; M. Doly; M. Duban; B. Favier; I. Madelaine-Chambrin; C. Ollivier; M. Paul; I. Princet; E. Serafini-Fougereau; F. Tabary; J.F. Tournamille; J.B. Rey 2014 |
10.1007/s10269-014-2366-7 |
|
Pharmaco imaging study of the effects of Debio 1143, a new orally available IAP inhibitor, in a triple negative breast cancer model A. Oudot; O. Raguin; L. Bauche; F. Bichat; A. Vaslin; H.MabyEl Hajjami; C. Zanna; G. Vuagniaux; P. Fumoleau; F. Brunotte; B. Collin 2014 |
10.1158/1538-7445.AM2014-2757 |
|
Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial E.M. Roth; J.Jp Kastelein; C.P. Cannon; M. Farnier; J.M. McKenney; T. DiCioccio; A. Brunet; G. Manvelian; W.J. Sasiela; M.T. Baccara-Dinet; J. Zhao; J.G. Robinson 2020 |
10.1016/j.jacl.2020.07.009 |
|
Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma M. Maillard; C. Chevreau; F. Le Louedec; M. Cassou; C. Delmas; L. Gourdain; J.Y. Blay; D. Cupissol; E. Bompas; A. Italiano; N. Isambert; C. Delcambre-Lair; N. Penel; F. Bertucci; C. Guillemet; J. Plenecassagnes; S. Foulon; E. Chatelut; A. Le Cesne; F. Thomas 2020 |
10.3390/cancers12123647 |
|
Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus P. Lancia; T.Adam de Beaumais; V. Elie; F. Garaix; M. Fila; F. Nobili; B. Ranchin; P. Testevuide; T. Ulinski; W. Zhao; G. Deschenes; E. Jacqz-Aigrain 2018 |
10.1007/s00467-017-3881-3 |
|
Pharmacokinetic and Pharmacodynamic Characterization of Graspa Versus Native L-Asparaginase in Combination with Cooprall Chemotherapy in a Phase 3 Randomized Trial for the Treatment of Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01 51851 7) X. Thomas; Y. Bertrand; A. Baruchel; N. Blin; E. Tavernier; S. Ducassou; N. Vey; V. Gandemer; V. Cacheux; F. Mazingue; E. Raffoux; G. Plat; J. Fernandes; M. Poiree; L. Fornecker; J.L. Stephan; M. Hunault; A. Auvrignon; T. Leguay; S. Lepretre; A. Ferster; I. Pellier; E. Plouvier; C. Schmitt; C. Bonin; Y. Godfrin; I.El Hariry 2015 |
|
|
Pharmacokinetic and Pharmacodynamic Characterization of Graspa Versus Native L-Asparaginase in Combination with Cooprall Chemotherapy in a Phase 3 Randomized Trial for the Treatment of Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01 51851 7) X. Thomas; Y. Bertrand; A. Baruchel; N. Blin; E. Tavernier; S. Ducassou; N. Vey; V. Gandemer; V. Cacheux; F. Mazingue; E. Raffoux; G. Plat; J. Fernandes; M. Poiree; L. Fornecker; J.L. Stephan; M. Hunault; A. Auvrignon; T. Leguay; S. Lepretre; A. Ferster; I. Pellier; E. Plouvier; C. Schmitt; C. Bonin; Y. Godfrin; I.El Hariry 2015 |
|
|
Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma A. Jouinot; B. Royer; S. Moeung; E. Chatelut; A. Bellesoeur; G. Assie; A. Thomas-Schoemann; J. Bertherat; F. Goldwasser; B. Blanchet 2018 |
|
|
Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma A. Jouinot; B. Royer; S. Moeung; E. Chatelut; A. Bellesoeur; G. Assie; A. Thomas-Schoemann; J. Bertherat; F. Goldwasser; B. Blanchet 2018 |
|
|
Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma A. Jouinot; B. Royer; S. Moeung; E. Chatelut; A. Bellesoeur; G. Assie; A. Thomas-Schoemann; J. Bertherat; F. Goldwasser; B. Blanchet 2018 |
|
|
Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease F. Goirand; I. Le Ray; M. Bardou 2014 |
10.1517/17425255.2014.939627 |
|
Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study A. Jouinot; B. Royer; E. Chatelut; S. Moeung; G. Assie; A. Thomas-Schoemann; J. Bertherat; F. Goldwasser; B. Blanchet 2018 |
10.1530/EC-18-0428 |
|
Pharmacokinetic interaction between pazopanib and cisplatin regimen D.C. Imbs; V. Dieras; T. Bachelot; M. Campone; N. Isambert; F. Joly; M. Jimenez; T. Lafont; E. Chatelut 2016 |
10.1007/s00280-015-2953-y |
|
Pharmacokinetic of tumor FDG uptake in subcutaneous and orthotopic preclinical models of breast cancer - Influence of administration route A. Oudot; J.M. Vrigneaud; O. Raguin; M. Guillemin; P. Provent; B. Collin; F. Brunotte 2016 |
|
|
Pharmacokinetics and pharmacodynamics relationship of regorafenib in chemorefractory metastatic colorectal cancer K. Boukerma; D. Vernerey; A. Henriques; I. Baumgartner; C. Tournigand; T. Andre; A. Hulin; B. Rousseau 2019 |
|
|
PHARMACOKINETICS AND SAFETY OF OLAPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS AND HEPATIC OR RENAL IMPAIRMENT C. Rolfo; J. de Vos-Geelen; N. Isambert; L.R. Molife; J.H. Schellens; J. De Greve; J.Y. Blay; L. Dirix; P. Grundtvig-Sorensen; A. Italiano; G. Jerusalem; R. Kristeleit; K. Leunen; M. Mau-Sorensen; R. Plummer; M. Learoyd; N. Baker; A. Fielding; A. Ravaud 2017 |